ACLARIS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.2 USD | +0.84% |
|
-3.23% | +14.29% |
| Mar. 19 | Aclaris Therapeutics, Inc. Announces Board Resignations | CI |
| Feb. 27 | Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 78.22 | 277.7 | 890.2 | 1,050 | 74.38 | 85.52 | - | - |
| Enterprise Value (EV) 1 | 78.22 | 277.7 | 890.2 | 820.5 | -44.73 | 14.28 | -71.9 | 5.374 |
| P/E ratio | -0.48 x | -5.39 x | -9.09 x | -11.8 x | -0.83 x | -1.23 x | -1.32 x | -1.34 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 18.5 x | 42.8 x | 132 x | 35.3 x | 2.38 x | 11 x | 9.84 x | 8.51 x |
| EV / Revenue | 18.5 x | 42.8 x | 132 x | 27.6 x | -1.43 x | 1.84 x | -8.28 x | 0.53 x |
| EV / EBITDA | -0.91 x | - | - | -9.21 x | 0.46 x | -0.15 x | 0.95 x | -0.07 x |
| EV / FCF | - | - | -17 x | -12 x | 0.56 x | -0.84 x | 1.27 x | -0.09 x |
| FCF Yield | - | - | -5.89% | -8.31% | 178% | -119% | 78.7% | -1,129% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 41,388 | 42,919 | 61,227 | 66,683 | 70,836 | 71,265 | - | - |
| Reference price 2 | 1.890 | 6.470 | 14.54 | 15.75 | 1.050 | 1.200 | 1.200 | 1.200 |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.227 | 6.482 | 6.761 | 29.75 | 31.25 | 7.756 | 8.688 | 10.05 |
| EBITDA 1 | -86.14 | - | - | -89.06 | -96.49 | -93.51 | -75.67 | -77.73 |
| EBIT 1 | -92.55 | -50.91 | -89.72 | -89.85 | -97.36 | -61.51 | -60.48 | -86.43 |
| Operating Margin | -2,189.59% | -785.44% | -1,327.07% | -302.01% | -311.55% | -793% | -696.14% | -860.15% |
| Earnings before Tax (EBT) 1 | -113.5 | -51.34 | -90.86 | -86.91 | -88.85 | -76.12 | -71.06 | -87.93 |
| Net income 1 | -161.4 | -51.02 | -90.86 | -86.91 | -88.48 | -73.66 | -70.72 | -83.6 |
| Net margin | -3,817.22% | -787.03% | -1,343.96% | -292.11% | -283.15% | -949.75% | -813.94% | -831.98% |
| EPS 2 | -3.900 | -1.200 | -1.600 | -1.330 | -1.270 | -0.9750 | -0.9071 | -0.8975 |
| Free Cash Flow 1 | - | - | -52.44 | -68.17 | -79.63 | -17 | -56.6 | -60.67 |
| FCF margin | - | - | -775.65% | -229.13% | -254.84% | -219.19% | -651.47% | -603.77% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.659 | 1.501 | 1.453 | 1.528 | 19.02 | 7.753 | 2.528 | 1.869 | 9.282 | 17.57 | 2 | 2.006 | 2.056 | 2.063 | 1.233 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.3 | -22.89 | -18.91 | -20.99 | -20.87 | -29.08 | -29.92 | -31.82 | -31.58 | -4.047 | -14.32 | -14.17 | -13.89 | -14.47 | -35.39 |
| Operating Margin | -1,223.33% | -1,525.18% | -1,301.24% | -1,373.95% | -109.76% | -375.07% | -1,183.47% | -1,702.25% | -340.2% | -23.03% | -715.81% | -706.39% | -675.44% | -701.5% | -2,870.48% |
| Earnings before Tax (EBT) 1 | -21.15 | -22.8 | -18.79 | -20.53 | -19.95 | -27.64 | -28.16 | -29.57 | -29.26 | -1.858 | -20.36 | -18.19 | -17.06 | -16.92 | -34.89 |
| Net income 1 | -21.15 | -22.8 | -18.79 | -20.53 | -19.95 | -27.64 | -28.16 | -29.57 | -29.26 | -1.491 | -20.32 | -17.96 | -16.43 | -16.04 | -34.89 |
| Net margin | -1,274.62% | -1,519.25% | -1,293.12% | -1,343.72% | -104.91% | -356.44% | -1,113.92% | -1,582.08% | -315.24% | -8.49% | -1,016.11% | -895.14% | -799.05% | -777.74% | -2,829.93% |
| EPS 2 | -0.3500 | -0.3700 | -0.3100 | -0.3100 | -0.3000 | -0.4100 | -0.4200 | -0.4200 | -0.4100 | -0.0200 | -0.2700 | -0.2357 | -0.2143 | -0.2086 | -0.2400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/24/22 | 5/10/22 | 8/3/22 | 11/8/22 | 2/23/23 | 5/8/23 | 8/7/23 | 11/6/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 230 | 119 | 71.2 | 157 | 80.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -52.4 | -68.2 | -79.6 | -17 | -56.6 | -60.7 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.61 | 0.45 | 0.31 | 0.61 | 1.31 | 1 | 1 | 1 |
| Capex / Sales | 38.16% | 6.99% | 4.56% | 2.03% | 4.19% | 12.89% | 11.51% | 9.95% |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
1.2
USD
Average target price
1.8
USD
Spread / Average Target
+50.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 85.52M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ACRS Stock
- Financials Aclaris Therapeutics, Inc.
